0001209191-22-047097.txt : 20220822
0001209191-22-047097.hdr.sgml : 20220822
20220822200559
ACCESSION NUMBER: 0001209191-22-047097
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220818
FILED AS OF DATE: 20220822
DATE AS OF CHANGE: 20220822
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Alam Kamran
CENTRAL INDEX KEY: 0001793412
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39536
FILM NUMBER: 221184904
MAIL ADDRESS:
STREET 1: 350 FIFTH AVENUE, SUITE 7530
CITY: NEW YORK
STATE: NY
ZIP: 10118
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc.
CENTRAL INDEX KEY: 0001806310
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 843199512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
BUSINESS PHONE: (214) 612-0000
MAIL ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-08-18
0
0001806310
Taysha Gene Therapies, Inc.
TSHA
0001793412
Alam Kamran
C/O TAYSHA GENE THERAPIES, INC.
3000 PEGASUS PARK DRIVE, STE 1430
DALLAS
TX
75247
0
1
0
0
Chief Financial Officer
Common Stock
2022-08-18
4
S
0
7476
3.87
D
290645
D
Common Stock
2022-08-19
4
S
0
11482
3.75
D
279163
D
Common Stock
2022-08-22
4
S
0
9717
3.50
D
269446
D
The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.80 to $3.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.61 to $3.85 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.40 to $3.71 inclusive.
/s/ Kamran Alam
2022-08-22